Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Veru Inc
(NQ:
VERU
)
0.7635
+0.0082 (+1.09%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Veru Inc
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Recap: Veru Q1 Earnings
February 09, 2022
Veru (NASDAQ:VERU) reported its Q1 earnings results on Wednesday, February 9, 2022 at 06:30 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Scheduled For February 9, 2022
February 09, 2022
Companies Reporting Before The Bell • Equinor (NYSE:EQNR) is projected to report quarterly earnings at $0.63 per share on revenue of $25.05 billion.
Via
Benzinga
5 Biotech Stocks to Buy to Benefit From Biden’s New Cancer Cabinet
February 04, 2022
Joe Biden is redoubling his efforts to fight cancer with a new "cancer cabinet." Here are the biotech stocks to buy that can benefit.
Via
InvestorPlace
Veru's Cancer Candidate Sabizabulin Gets FDA Fast Track Tag For COVID-19
January 31, 2022
The FDA has granted Fast Track designation to Veru Inc's (NASDAQ:
Via
Benzinga
Promising Developments in Breast Cancer Treatments Ahead in 2022
January 12, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 12, 2022 – USA News Group – So far in 2022, there have already been some impressive developments in the battle against...
Via
FinancialNewsMedia
Veru Posts Mixed Q4 Results
December 02, 2021
Veru Inc (NASDAQ: VERU) reported fourth-quarter FY21 sales growth of 32.8% year-on-year, to $15.65 million, missing the analyst consensus of $18.17 million. FC2...
Via
Benzinga
Veru: Q4 Earnings Insights
December 02, 2021
Veru (NASDAQ:VERU) reported its Q4 earnings results on Thursday, December 2, 2021 at 06:30 AM. Here's what investors need to know about the announcement. Earnings Veru...
Via
Benzinga
Veru: Q3 Earnings Insights
August 12, 2021
Shares of Veru (NASDAQ:VERU) rose 13.2% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 40.00% over the past year to...
Via
Benzinga
48 Biggest Movers From Yesterday
January 12, 2022
Gainers Splash Beverage Group, Inc. (NYSE: SBEV) shares jumped 70.6% to close at $1.80 on Tuesday after the company announced it received authorization to sell its TapouT...
Via
Benzinga
9 Consumer Staples Stocks Moving In Tuesday's Intraday Session
January 11, 2022
Gainers Veru (NASDAQ:VERU) shares moved upwards by 21.5% to $6.49 during Tuesday's regular session. As of 12:31 EST, this security is trading at a volume of 7.0...
Via
Benzinga
30 Stocks Moving In Tuesday's Mid-Day Session
January 11, 2022
Gainers TSR, Inc. (NASDAQ: TSRI) shares climbed 36.6% to $12.21 following Q2 results. The company reported Q2 revenue of $23.9 million, versus $16.1 million year over year....
Via
Benzinga
Earnings Outlook For Veru
August 11, 2021
On Thursday, August 12, Veru (NASDAQ:VERU) will report its last quarter's earnings. Here is Benzinga's preview of the company's release. What Are Earnings, Net Income, And...
Via
Benzinga
Why Jim Cramer Likes Grab Holdings
January 11, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Veru Inc. (NASDAQ:
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
January 06, 2022
On Thursday, 615 stocks hit new 52-week lows. Noteable 52-Week Lows: Sea (NYSE:SE) is the largest company in terms of market cap to set a new 52-week low this...
Via
Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
August 08, 2021
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...
Via
Benzinga
Exposures
Product Safety
How Good Are Veru's Earnings? | Return On Capital Employed
December 03, 2021
According to Benzinga Pro data, during Q4, Veru (NASDAQ:VERU) posted sales of $15.65 million. Earnings were up 34.84%, but Veru still reported an overall loss of $1.87 million. In...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates
December 02, 2021
A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Moderna, Pfizer-BioNTech Ink New Vaccine Deals With UK, GSK-Vir Antibody Show Activity Against Omicron, Chemomab Gets Clearance
December 02, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus U.K. Signs Deal to Buy Incremental COVID-19 Vaccines From Moderna And Pfizer-...
Via
Benzinga
Exposures
COVID-19
Earnings Scheduled For December 2, 2021
December 02, 2021
Companies Reporting Before The Bell • EHang Holdings (NASDAQ:EH) is expected to report earnings for its third quarter. • LightInTheBox Holding (NYSE:LITB) is...
Via
Benzinga
Earnings Outlook For Veru
December 01, 2021
Veru (NASDAQ:VERU) is set to give its latest quarterly earnings report on Thursday, 2021-12-02. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
10 Consumer Staples Stocks Moving In Monday's After-Market Session
November 22, 2021
Gainers 111 (NASDAQ:YI) shares rose 3.81% to $4.35 during Monday's after-market session. The market value of their outstanding shares is at $360.4 million. The company's, Q3...
Via
Benzinga
Cramer Gives His Take On Change Healthcare, Veru And More
November 11, 2021
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Change Healthcare Inc. (NASDAQ: CHNG) is a good, steady firm. Cramer said with Veru Inc. (NASDAQ: VERU)...
Via
Benzinga
The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight
September 19, 2021
Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical...
Via
Benzinga
Exposures
Product Safety
Why Veru Stock Vaulted Higher Today
September 02, 2021
An analyst raised his price target for the stock.
Via
The Motley Fool
Why Veru Stock Blasted Higher on Friday
August 27, 2021
An analyst argues that the company has far more value than many realize.
Via
The Motley Fool
Veru Stock Gains After Q3 Result Tops Estimates
August 12, 2021
Veru Inc (NASDAQ: VERU) reported third-quarter FY21 sales growth of 71% year-on-year, to $17.66 million, beating the analyst consensus of $14.10 million. FC2...
Via
Benzinga
Veru's Enobosarm Efficacy Correlates with Androgen Receptor Levels in Metastatic Breast Cancer Patients
June 07, 2021
Veru Inc (NASDAQ: VERU) has announced additional clinical results from the Phase 2 study evaluating enobosarm, a selective androgen receptor (AR) targeting agent,...
Via
Benzinga
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
August 12, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (...
Via
Benzinga
Exposures
Product Safety
Earnings Scheduled For August 12, 2021
August 12, 2021
Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter. • ITeos Therapeutics (NASDAQ:ITOS...
Via
Benzinga
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
May 31, 2021
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-...
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.